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I read with interest the article by van Duin and colleagues
regarding tigecycline resistance following tigecycline therapy for
carbapenem-resistant Klebsiella pneumoniae bacteriuria, which
has important implications and deserves comment [1].
Their study described resistance following tigecycline therapy
in bacteriuric patients, most of which had indwelling urinary
catheters, i.e., catheter-associated bacteriuria (CAB) [1]. There
are several factors that predispose to resistance with any anti-
biotic, but each antibiotic has an inherent resistance potential
that may be considered as having a ‘low resistance potential’, e.g.,
tigecycline or a ‘high resistance potential’, e.g. ampicillin, genta-
micin, ceftazidime, ciproﬂoxacin and macrolides. If ‘low resis-
tance potential’ antibiotics, e.g., tigecycline, are given in full or
high dose, their resistance potential remains low. Resistance to
any antibiotic, including tigecycline, may occur with prolonged
exposure to sub-therapeutic serum or tissue (urinary) concen-
trations [2]. With usual dosing, sub-therapeutic antibiotic con-
centrations are often present in abscesses and devices associated
with colonization or infection, e.g., urinary catheters (CAB).
Colonization or infections by aerobic Gram-negative bacilli
(GNBs), particularly due to multidrug-resistant organisms
(MDROs), e.g., carbapenem-resistant Klebsiella pneumoniae, is
therapeutically problematic. With GNB MDROs colonized uri-
nary catheters a bioﬁlm is formed that renders embeddedClinical Microbiology and Infection © 2015 European Society of Cbacteria ‘resistant’ even to urinary therapeutic antibiotic levels.
Antimicrobials that cannot penetrate the bioﬁlm of a urinary
catheter are usually ineffective in eliminating GNBs from the
bioﬁlm/catheter, but exposure to sub-therapeutic antibiotic
levels predisposes to resistance.
In a patients with indwelling urinary catheters with a positive
urinalysis, e.g., pyuria (> 50 white blood cells per high-power
ﬁeld) and a positive urine culture (> 100,000 col/ml) for
GNB, then the initial intervention in CAB should be to replace
the catheter and repeat urinalysis and urine culture. In most
cases, replacement of the urinary catheter alone eliminates
CAB by removing the nidus of infection of the catheter bioﬁlm.
Unless the patient is an immunocompromised host (predis-
posed to urosepsis from urinary tract colonization/infection),
an important principle of antimicrobial stewardship is to avoid
unnecessary treatment of CAB.
In the era of GNB MDROs, tigecycline has become an
important part of the antimicrobial armamentarium and has been
particularly useful against MDRO K. pneumoniae, Escherichia coli
and Acinetobacter baumannii (Pseudomonas aeruginosa and most
Proteus sp. are naturally resistant to tigecycline). Along with
gentamicin and colistin, tigecycline is one of the few antibiotics
that is effective against highly resistant MDROs, e.g., New Delhi
metallo-β-lactamase. Therefore, it is important to optimize tige-
cycline use against problempathogens,which is best accomplished
by selective use, i.e. treating infections (versus colonization) and
by using pharmacokinetic-based high-dose regimens [2].
Since tigecycline is eliminated primarily via the biliary route,
urinary concentrations of tigecycline are expectedly much less
(22% of serum levels) than in serum or non-biliary ﬂuids.
Tigecycline treatment of infections with the usual recom-
mended doses results in very low urinary concentrations
(0.15 μg/mL). If tigecycline is used to treat CAB (if the urinary
catheter is not removed/replaced), then high-dose tigecycline,
using dosing based on pharmacokinetic principles, achieves
higher urine levels (0.3–0.6 μg/mL) and has the best chance of
cure and minimizes potential resistance [3].
We rely on tigecycline to treat a variety of serious systemic
infections due to problematic Gram-positive and Gram-
negative pathogens. When treating uropathogens with tigecy-
cline, we use a higher loading and daily maintenance dose than
recommended by the manufacturer. Over the years, we have
had considerable experience in using high dose (loading dose)
and high (maintenance) single daily dose (every 24 h versus
every 12 h) therapy for serious infections. Using pharmacoki-
netic principles, it is possible to eradicate organisms even in
difﬁcult locations, e.g., urine by increasing tigecycline doses to
achieve therapeutic urine levels (MICs of nearly all uropath-
ogens to tigecycline is < 0.2 μg/ml) (Table 1) [2,3].Clin Microbiol Infect 2015; 21: e39–e40
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TABLE 1. Tigecycline dosing regimens: tigecycline pharmacokinetics in serum and urine
Loading dose Maintenance dose
Usual recommended doses
Recommended dose 100 mg (intravenous) × 1 50 mg (intravenous) 12-hourly
Peak serum concentration 1.5 μg/mL 0.75 μg/mL
Peak urinary concentration 0.3 μg/mL 0.15 μg/mL
Suggested doses for urinary tract infections
Suggested dose 200 mg (intravenous) × 1 100 mg (intravenous) 24-hourly
Peak serum concentration 3.0 μg/mL 1.5 μg/mL
Peak urinary concentration 0.6 μg/mL 0.3 μg/mL
Suggested doses for serious systemic infections/multidrug-resistant urinary tract infections
Suggested dose 400 mg (intravenous) × 1 200 mg (intravenous) 24-hourly
Peak serum concentration 6.0 μg/mL 3.0 μg/mL
Peak urinary concentration 1.2 μg/mL 0.6 μg/mL
Adapted from Cunha BA, Antibiotic Essentials (12th ed), Jones & Bartlett, Sudbury MA 2013; pp. 699–703; Cunha BA. Pharmacokinetic considerations regarding tigecycline for
multidrug-resistant (MDR) Klebsiella pneumoniae or MDR Acinetobacter baumannii urosepsis. J Clin Microbiol 2009; 47: 1613.
Note: Tigecycline pharmacokinetic parameters are as follows. Primary mode of elimination is biliary; serum half life, 42 h; excreted unchanged in urine, 22%; plasma protein
binding, 89%; volume of distribution, 8 L/kg.
e40 Clinical Microbiology and Infection, Volume 21 Number 5, May 2015 CMIIn the study by van Duin et al., most of their patients had
CAB [1]. As urinalyses were not included, it is impossible to
differentiate CAB colonization from infection. It was also not
mentioned if replacement in those with indwelling urinary
catheters was attempted ﬁrst before initiating tigecycline
therapy. It would appear that the most important determinant
of tigecycline resistance in their study was sub-therapeutic
urinary concentrations of tigecycline in treating CAB.
Although dose and duration of tigecycline therapy were not
given, it is likely that standard recommended doses of tigecy-
cline were used, e.g., one 100 mg (intravenous) initial loading
dose followed by 50 mg (intravenous) every 12 h (manufac-
turer’s recommended dosing regimen). Using the recom-
mended doses of tigecycline, it is not at all surprising that in
some patients resistance developed to sub-therapeutic tigecy-
cline urinary concentrations [2].
Our tigecycline experience is extensive and tigecycline has
become a ‘problem solver’ rather than a problem-causing
antibiotic, i.e. adverse effects, resistance, etc. When unable
to replace urinary catheters and if the colonizing/infecting
uropathogen is an MDRO (non-P. aeruginosa or Proteus sp.),
then we use ‘high–dose’ tigecycline therapy. Based on its
pharmacokinetic parameters, we have never used the uro-
pathogen recommended doses of tigecycline. There seems to
be no pharmacokinetic rationale in dosing an antibiotic with a
serum half-life of 42 h on a 12-hourly basis. We have always
used either one of two high-dose regimens, i.e., high dose for
serious systemic infections and higher doses for lower UTIs
[2–4]. We have not had side effects using high-dose tigecy-
cline therapy, even with prolonged high-dose use, in our pa-
tient experience. In the rare patient who develops nausea onClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infecthigh-dose tigecycline, nausea is easily eliminated by doubling
the volume of the diluent and doubling the antibiotic infusion
time.
In conclusion, if it is at all possible, the initial approach to
CAB should be to replace the catheter and repeat urinary al-
bumin and urinary creatine measurements. If colonization/
infection persists, select a renally eliminated antibiotic to which
the uropathogen is susceptible. Before tigecycline is considered,
other renally eliminated antibiotics, e.g., nitrofurantoin, fosfo-
mycin, should be tried. If therapy is not optional and the GNB
MDRO uropathogen is not susceptible to other antibiotics,
then tigecycline may be considered [5]. In this setting, we use
high-dose tigecycline for optimal clinical effectiveness, which
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